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A B S T R A C T
Background
Acute upper respiratory tract infections (URTIs), including the common cold and rhinosinusitis, are common afflictions that cause
discomfort and debilitation and contribute significantly to workplace absenteeism. Treatment is generally by antipyretic and deconges-
tant drugs and sometimes antibiotics, even though most infections are viral. Nasal irrigation with saline is often employed as an adjunct
treatment for URTI symptoms despite a relative lack of evidence for benefit in this clinical setting. This review is an update of the
Cochrane review by Kassel et al, which found that saline was probably effective in reducing the severity of some symptoms associated
with acute URTIs.
Objectives
To assess the effects of saline nasal irrigation for treating the symptoms of acute URTIs.
Search methods
We searched CENTRAL (2014, Issue 7), MEDLINE (1966 to July week 5, 2014), EMBASE (1974 to August 2014), CINAHL (1982
to August 2014), AMED (1985 to August 2014) and LILACS (1982 to August 2014).
Selection criteria
Randomised controlled trials (RCTs) comparing topical nasal saline treatment to other interventions in adults and children with
clinically diagnosed acute URTIs.
Data collection and analysis
Two review authors (DK, BM) independently assessed trial quality with the Cochrane ’Risk of bias’ tool and extracted data. We
analysed all data using the Cochrane Review Manager software. Due to the large variability of outcome measures only a small number
of outcomes could be pooled for statistical analysis.
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Main results
We identified five RCTs that randomised 544 children (three studies) and 205 adults (exclusively from two studies). They all compared
saline irrigation to routine care or other nose sprays, rather than placebo. We included two new trials in this update, which did not
contribute data of sufficient size or quality to materially change the original findings. Most trials were small and we judged them to be
of low quality, contributing to an unclear risk of bias. Most outcome measures differed greatly between included studies and therefore
could not be pooled. Most results showed no difference between nasal saline treatment and control. However, one larger trial, conducted
with children, did show a significant reduction in nasal secretion score (mean difference (MD) -0.31, 95% confidence interval (CI) -
0.48 to -0.14) and nasal breathing (obstruction) score (MD -0.33, 95% CI -0.47 to -0.19) in the saline group. However, a MD of -
0.33 on a four-point symptom scale may have minimal clinical significance. The trial also showed a significant reduction in the use of
decongestant medication by the saline group. Minor nasal discomfort and/or irritation was the only side effect reported by a minority
of participants.
Authors’ conclusions
Nasal saline irrigation possibly has benefits for relieving the symptoms of acute URTIs. However, the included trials were generally too
small and had a high risk of bias, reducing confidence in the evidence supporting this. Future trials should involve larger numbers of
participants and report standardised and clinically meaningful outcome measures.
P L A I N L A N G U A G E S U M M A R Y
Nasal saline irrigation for acute upper airway infection symptoms
Review question
Does the addition of nasal saline spray or wash to usual care or placebo reduce the severity of symptoms or speed the recovery of adults
and children with cold and flu symptoms that have been present for less than four weeks?
Background
Acute upper respiratory tract infections (URTIs) include colds, influenza and infections of the throat, nose or sinuses. They are usually
self limiting viral infections, though sometimes symptoms may persist for many weeks beyond the clearance of the initial infection, with
or without establishment of secondary bacterial infections. The aim of treatment is predominantly for relief of symptoms, though some
treatments may have a role in reducing the duration of post-viral symptoms, such as cough. Saline nose spray and larger volume nasal
washes have become more popular as one of many treatment options for URTIs, and they have been shown to have some effectiveness
for chronic sinusitis and following nasal surgery. However, little is known about their effectiveness in the treatment of acute URTI or
which symptoms they may be effective for.
Study characteristics
We identified five studies, with a total of 749 participants enrolled and 565 participants providing data, which addressed the research
question and met the inclusion criteria. They all compared saline irrigation with routine care or other nose sprays. These studies covered
a wide range of ages, countries, sample sizes, dosing methods and frequency, and time since onset of URTI symptoms. They were also
highly variable in their design and the symptoms that were measured. This is not surprising due to the lack of consistent measures of
URTI symptoms and signs. This resulted in very few common outcome measures that could be combined across these five studies. The
evidence is current to August 2014.
Key results
The two additional studies included since the original systematic review have not contributed data of sufficient size or quality to
materially change the original findings. Only the largest study, which studied 401 children aged 6 to 10 years, found significant
reductions in a number of symptoms, including nasal secretions, sore throat, nasal breathing score and nasal obstruction, as well as
reduced use of additional nasal decongestant medications. It also reported a significant improvement in the health status score. There
was a reduction in the outcome of time to resolution of symptoms, which was reported in two trials on adult participants, but the
difference was not clinically significant. Nasal saline is safe but may cause minor adverse effects, such as irritation or a burning sensation,
particularly with products using higher flows or concentrations.
Quality of the evidence
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Most studies were small and had significant shortcomings in the design or implementation of the research. Further studies, preferably
larger in size and using common outcome measures, are needed to establish the potential for the role of nasal saline irrigation in reducing
the severity and duration of acute URTI symptoms, secondary infections and possibly antibiotic usage.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Normal saline plus standard treatment compared to standard treatment alone for acute upper respiratory tract infections
Patient or population: patients with acute upper respiratory tract infections
Settings: outpatient or community setting
Intervention: normal saline plus standard treatment
Comparison: standard treatment alone
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No. of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Standard treatment
alone
Normal saline plus stan-
dard treatment
Mean days to wellness
Patient reports
The mean days to well-
ness in the control groups
was
9.24 days
The mean days to well-
ness in the intervention
groups was
0.74 lower
(2.58 lower to 1.11
higher)
111
(2 studies)
⊕©©©
very low1,2,3
Antibiotic usage
Patient-reported usage
Study population OR 0.65
(0.29 to 1.46)
422
(2 studies)
⊕©©©
very low3,4
89 per 1000 60 per 1000
(27 to 124)
Moderate
88 per 1000 59 per 1000
(27 to 123)
Sore throat
Patient-reported symp-
toms Scale from: 1 to 4
Follow-up: 3 weeks5
The mean sore throat in
the control groups was
1.23 points
The mean sore throat in
the intervention groups
was
0.14 lower
390
(1 study)
⊕⊕©©
low4
4
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(0.24 to 0.04 lower)
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; OR: odds ratio
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1Bias is likely in the included studies as adequate blinding is not possible with this intervention.
2There is inconsistency in treatment effects as each study showed trends on either side of the null effect line.
3The included studies had small numbers of participants. The resulting confidence intervals around the estimated effect vary from minor
to large, clinically significant effects.
4The study was assessed as having a high risk of bias in both randomisation and blinding, with other domains unclear.
5The mean time of follow-up was not specified. Patients were all reported to be followed up within three weeks.
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B A C K G R O U N D
Description of the condition
Acute upper respiratory tract infections (URTIs) involve the upper
airways (the nose, sinuses, larynx and pharynx) and include the
common cold, influenza, rhinitis, sinusitis, laryngitis, pharyngitis,
tonsillitis and otitis media. Acute infections are defined as those
with symptoms lasting up to 28 days (Meltzer 2006).
Acute URTIs are common, can vary in severity from mild to dis-
tressing and debilitating and are a major cause of lost days of work
and schooling. The economic impact of the common cold alone
on workplace absenteeism is estimated to be billions of dollars
(Bramley 2002).
Usual treatments for URTIs are symptomatic. Treatment may in-
clude antipyretic and analgesic drugs, mucolytics, expectorants
and decongestants (NICE 2008; Simasek 2007).While acute UR-
TIs are mainly caused by viruses, antibiotics are often prescribed
(Nash 2002). This may lead to increased antibiotic resistance and
adverse outcomes, as well as being unnecessary for the patient
(NICE 2008).
Description of the intervention
Saline can be delivered to the nose as a large-volume wash using
reservoir pots and tubing, or in a small volume via spray devices
that deliver a fine mist or jet of saline into the nose. The usual con-
centration is ’normal saline’, which approximates an iso-osmolar
fluid. Hypertonic saline is sometimes used to deliver a stronger
concentration of fluid to the nasal cavity and sinuses.
How the intervention might work
Saline irrigation of the nose, which is a popular treatment for
sinonasal conditions, is believed to alleviate URTI symptoms by
clearing excess mucus, reducing congestion and improving breath-
ing (Tomooka 2000). It is thought to improve mucociliary clear-
ance by increasing the ciliary beat frequency (Talbot 1997). As
well as relieving sinonasal symptoms, saline irrigation may remove
infectious material from the sinuses and reduce cough associated
with postnasal drip (Kaliner 1998). There is evidence for the ef-
fectiveness of nasal saline irrigation for chronic sinusitis (Rabago
2002) and allergic rhinitis (Garavello 2003). It has been used as
monotherapy or as an adjunct to other treatments, such as oral an-
tihistamines. It is available commercially in various concentrations
and formulations of salt and water combinations and is usually
delivered by atomised spray or in larger volumes for lavage.
Why it is important to do this review
Nasal saline treatmentmay reduce the burden of disease andwork-
place absenteeism and reduce the over-prescription of antibiotics
for acute URTIs. One non-systematic review of the existing litera-
ture found thatmost trials of nasal saline in acute URTIs were very
small, with some being uncontrolled experiments, and concluded
that the evidence in favour of nasal saline was “fair” (Papsin 2003).
A Cochrane Review assessed nasal saline irrigation as a treatment
for chronic rhinosinusitis and found that it may be useful in pro-
viding symptomatic relief, without significant side effects (Harvey
2007).
This systematic review evaluates the efficacy of saline irrigation in
the treatment of acute URTIs, to determine whether saline nasal
irrigation improves respiratory symptoms of acute URTIs.
O B J E C T I V E S
To assess the effects of saline nasal irrigation for treating the symp-
toms of acute URTIs.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs) comparing topical nasal
saline treatment (liquid, drops or spray) with at least one other in-
tervention or placebo. We excluded studies trialing another ther-
apy where saline irrigation was used as a control treatment. We
excluded non-RCTs or non-comparative studies.
Types of participants
Adults and children diagnosed with acute URTIs featuring nasal
and/or sinus symptoms for less than four weeks. (Types of acute
URTIs include rhinosinusitis, pharyngitis, otitis media, tonsillitis,
common cold and influenza).
We excluded studies involving patients with allergic respiratory
symptoms, chronic respiratory infections or chronic diseases with
respiratory features, such as cystic fibrosis, or those recovering from
sinus surgery. We also excluded studies that examined the preven-
tion of developing URTIs from regular use of saline irrigation.
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Types of interventions
We proposed to include the following interventions.
1. Nasal lavage, irrigation or similar topical nasal liquid saline
treatment, compared with a placebo.
2. Nasal lavage, irrigation or similar topical nasal liquid saline
treatment, compared with other standard treatment.
3. Nasal saline plus standard treatment compared with
standard treatment alone.
We included studies using atomised sprays or irrigation with larger
volumes of saline solutions and all types of commercially available
saline preparations and concentrations, including isotonic and hy-
pertonic solutions.
Types of outcome measures
Primary outcomes
1. Change in severity of acute URTI-related symptoms (for
example, nasal discharge, congestion, sneezing, headache, sore
throat) over periods up to 28 days.
2. Time to resolution of symptomatic illness.
Secondary outcomes
1. Adverse events associated with treatment.
2. Days off work or school.
3. Antibiotic and URTI medication use.
Search methods for identification of studies
Electronic searches
For this update we searched the Cochrane Central Register of
Controlled Trials (CENTRAL 2014, Issue 7) (accessed 13 Au-
gust 2014), which contains the Acute Respiratory Infections (ARI)
Group’s Specialised Register, MEDLINE (May 2009 to July week
5, 2014), EMBASE (May 2009 to August 2014), CINAHL (May
2009 to August 2014), AMED (May 2009 to August 2014) and
LILACS (May 2009 to August 2014). Details of the previous
search strategy are in Appendix 1.
We used the search terms described in Appendix 2 to searchMED-
LINE and CENTRAL.We combined theMEDLINE search with
the Cochrane Highly Sensitive Search Strategy for identifying
randomised trials in MEDLINE; sensitivity- and precision-max-
imising version (2008 revision); Ovid format (Lefebvre 2011).
We modified the search terms to search EMBASE (Appendix
3), CINAHL (Appendix 4), AMED (Appendix 5) and LILACS
(Appendix 6). There were no language or publication restrictions.
Searching other resources
We checked the Australian New Zealand Clinical Trial Register
database (http://www.anzctr.org.au/) and the US National Insti-
tutes of Health (http://www.clinicaltrials.gov) for relevant studies.
We sought evidence of any adverse effects of saline nasal irrigation
from other sources, including the US Food and Drug Adminis-
tration’sMedWatch (www.fda.gov/medwatch), the UKMedicines
Control Agency (https://www.gov.uk/government/organisations/
medicines-and-healthcare-
products-regulatory-agency) and the Australian Adverse Drug Re-
actions Bulletin (http://www.health.gov.au).
We made and handsearched a list of relevant journals. This in-
cluded: Archives of Otolaryngology, Laryngoscope, Archives of Family
Medicine, Journal of Family Practice, Clinical Otolaryngology and
American Journal of Otolaryngology.
We also identified studies by checking the bibliographies of all
studies retrieved.We contacted authors of relevant trials regarding
any recent unpublished work.
Data collection and analysis
We considered, processed and reported data from the included
trials in close consultation with the Cochrane Handbook for Sys-
tematic Reviews of Interventions version 5.1.0 (Higgins 2011).
Selection of studies
In this 2014 update, two review authors (DK,CW) independently
screened the titles and abstracts to exclude studies that were clearly
irrelevant. We compared the full texts of the potentially relevant
studies to the eligibility criteria. In the original search, one review
author (JK) selected the studies. Two review authors (DK, GS)
checked the results.
Data extraction and management
Two review authors (DK, BM) independently extracted and sum-
marised details of the studies using a data extraction sheet. Data
extracted included year and country of study, study population,
methodological quality, type of saline solution used, any adverse
events and outcomes.We contacted trial authors for missing infor-
mation where possible. However, the authors of one paper in the
updated search replied to questions about methodology but pro-
videdno further information (Wang 2009).Wemanaged and anal-
ysed data using Review Manager software, version 5.3 (RevMan
2014).
Assessment of risk of bias in included studies
We assessed trials for risk of bias and appropriateness for inclusion
as per the Cochrane Handbook for Systematic Reviews of Interven-
tions version 5.1.0 (Higgins 2011). We undertook ’Risk of bias’
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assessment by evaluating the following components for each in-
cluded study.
1. The method of generation of the randomisation sequence -
if it delivered a known chance allocation to each given group, but
individual allocation could not be anticipated.
2. The method of allocation concealment - considered
’adequate’ when the assignment could not be foreseen.
3. Who was masked or unmasked to the intervention
(participants, clinicians, outcome assessors).
4. Participants lost to follow-up in each arm of the study (split
into post-randomisation exclusions and later losses if possible)
and whether participants were analysed in the groups to which
they were originally randomised (intention-to-treat).
In addition, we collated aspects related to follow-up, participants
lost to follow-up, protocol violations and sample size determina-
tions. We recorded the information in the ’Risk of bias’ tables and
gave a description of the quality of each study, based on a summary
of these components.
Measures of treatment effect
Wemeasured treatment effects using odds ratio for categorical out-
comes and mean difference for continuous measures such as days
of illness and symptom scores. Where continuous outcomes were
measuring the same outcome, such as symptom score, but using
different scales we used standardised mean difference to assess the
potential to combine such studies in a meta-analysis.
Unit of analysis issues
The unit of analysis was the individual patient who was ran-
domised in eachRCT,which allowed standard analysis techniques.
Cluster-randomisation did not occur in the included studies.
Dealing with missing data
Where missing data were present, we intended to contact the orig-
inal investigators to request the missing data. We assumed that
missing data were missing at random. Where studies were missing
more than 40% of their data, we intended to conduct sensitivity
analysis to explore the nature of the missing data, where the data
were available to do this.
Assessment of heterogeneity
We assessed heterogeneity for results measuring similar outcomes.
Firstly, we assessed heterogeneity by the degree of overlap in confi-
dence intervals. Where there was little or no overlap, we assumed
significant heterogeneity. Secondly, we looked at the Chi2 test and
assumed that for results with a P value greater than 0.1, significant
heterogeneity was likely. Thirdly, we looked at the I2 statistic and
assumed that results greater than 40% indicated concern about
heterogeneity. Where we suspected significant heterogeneity, we
did not report totals.
Assessment of reporting biases
We attempted to retrieve all the collected data from all included
studies (published and unpublished). We intended to compare the
results of studies funded by manufacturers of nasal saline delivery
products versus those that were funded independently. We also
intended to compare the results of published and unpublished
studies.We compared the outcomes reported in the trial against the
protocol for the studies, whenever possible, to assess for reporting
bias.
Data synthesis
We undertook meta-analysis for outcomes where there were suffi-
cient comparable data using random-effects methods and hetero-
geneity did not preclude pooling of results. We conducted narra-
tive synthesis of results where it was not possible to pool outcome
data.
Subgroup analysis and investigation of heterogeneity
We intended to analyse by subgroups in the event of multiple
outcome measures with significant heterogeneity. Groupings that
may have been relevant to this study include gender, geographical
location, age of participants and type of intervention. This was
not relevant to this review as there were insufficient studies to pool
data.
Sensitivity analysis
We intended to consider sensitivity analysis to investigate the ef-
fects of published versus unpublished studies, the quality of in-
cluded studies and the different types of nasal saline delivery.How-
ever, these analyses were not required in this review owing to the
small number of outcomes for a small number of included studies.
GRADE and ’Summary of findings’ table
In this update, we used theGRADEapproach to interpret themain
findings and report outcome-specific information and the overall
quality of evidence from the included studies in each compari-
son (GRADE 2009). We used the GRADE profiler (GRADEpro
2014) software to import data fromReviewManager 5.3 (RevMan
2014) to create a ’Summary of findings’ table.We downgraded the
evidence from ’high quality’ by one level (two if severe) for study
limitations that are likely to have a serious impact on the results,
including bias for blinding, inconsistency in treatment effects and
imprecision (studies with small numbers had confidence intervals
that included minor to very large effect sizes).
R E S U L T S
8Saline nasal irrigation for acute upper respiratory tract infections (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Description of studies
Results of the search
The initial (2009) search yielded the following results: 146 articles
inMEDLINE, 68 inEMBASE, 49 inCENTRAL, 22 inCINAHL
and none in AMED or LILACS. Of the total 285 trials retrieved,
we excluded 280 based on a review of titles and abstracts. Of the
five remaining trials, we assessed three as meeting the inclusion
criteria and excluded two as not meeting the minimum quality
criteria.
This 2014 update identified 75 additional records from searches
covering April 2009 to August 2014, with the following results:
18 articles in MEDLINE, 32 in EMBASE, 14 in CENTRAL, 10
in CINAHL, none in AMED and one in LILACS. Of the articles
found in these searches, we excluded 46 based on a review of
titles and abstracts as not meeting the inclusion criteria. We only
selected one study as meeting the inclusion criteria after reading
the full text and included it in the updated review (Wang 2009).
We included one further study in this updated review (King 2012,
unpublished). This unpublished trial was brought to the attention
of the review team by one of the authors (DK). His role in the trial
was as a supervisor and clinician. The ’Risk of bias’ assessment and
data extraction were undertaken by an independent author (BM)
who had no role in this trial.
A flowchart of study selection is attached (Figure 1).
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Figure 1. Study flow diagram.
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Included studies
See Characteristics of included studies.
Adam 1998 randomised 143 adults in the USA with clinically
diagnosed acute rhinosinusitis or common cold to one of three
groups: hypertonic nasal saline irrigation, normal saline irrigation
or no treatment (control). One hundred and nineteen adults com-
pleted follow-up and contributed data for analysis.
Bollag 1984 studied 74 children in the USA with clinically diag-
nosed acute URTIs that were randomised to treatment with nor-
mal saline drops, phenylephrine drops or no treatment. Forty-six
participants were analysed (28 were lost to follow-up).
Slapak 2008 studied 401 children in theCzechRepublic with clin-
ically diagnosed common cold or influenza that were randomised
to receive standard treatment with or without adjunct nasal irriga-
tion with isotonic saline. Three hundred and ninety contributed
data for analysis. The intervention group was further subdivided
into three subgroups using different delivery strengths: fine spray,
medium jet flow and fine spray eye and nose wash. Each subgroup
used the same solution of commercial isotonic seawater. Results
were reported for each subgroup and for the saline group as a
whole; this review considers the results for the saline group as a
whole. Data were reported as mean scores at entry into the study
and at a second visit (up to three weeks) with standard deviations.
Findings were reported as significant with a P value less than 0.05.
Data on symptom scores at earlier time points prior to three weeks
were not available, so could not be combined with other studies
that all reported outcomes at earlier time points, therefore we have
reported the findings descriptively in the text.
Wang 2009 randomised 69 children aged three to 12 years, diag-
nosed with acute sinusitis and who had symptoms for more than
seven days, to either usual care (which included systemic antibi-
otics, mucolytics and nasal decongestants) or usual care plus nasal
saline irrigation. Sixty-seven contributed data for analysis. Partici-
pants completed symptoms diaries (averaged over seven days) and
these results were considered in this review. Participants also com-
pleted a sinus X-ray (Water’s projection), a nasal smear, quality of
life scores and nasal peak expiratory flow rates, but no raw data
were presented. These data were also not available from the trial
authors and therefore not included in this review.
King 2012 met the inclusion criteria as it randomised 62 adults
with clinically diagnosed acute URTIs to receive standard treat-
ment (analgesia, lozenges and cold and flu medications), or stan-
dard treatment plus isotonic saline nasal spray. Results were re-
ported using symptom diaries and included first day of wellness;
daily symptom scores measured on a four-point scale; days off
work or school; return visits to general practice and use of antibi-
otics. Only 33 participants contributed data for analysis (see Risk
of bias in included studies).
Excluded studies
Two trials were excluded from the original review after evaluation
(Inanli 2002; Passali 2005). The main reasons for exclusion were
lack of description of randomisation, unblinded studies and in-
adequate data analysis. Mucociliary clearance, the only outcome
measure used by Inanli 2002, was further assessed to be an un-
suitable measure for acute URTI symptoms. Passali 2005 was ex-
cluded due to doubt as to proper randomisation of the study. For
details, see Characteristics of excluded studies table. We also ex-
cluded these trials from the 2014 review, but on the grounds of
not meeting the inclusion criteria, rather than high risk of bias.
Risk of bias in included studies
A summary of the risk of bias is displayed in Figure 2 and Figure
3. Most studies had some degree of bias as outlined below. For
further details, see the Characteristics of included studies table.
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Figure 2. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study.
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Figure 3. ’Risk of bias’ graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
Allocation
Only King 2012 used computer-generated randomisation to allo-
cate participants to study groups (low risk of bias). Two trials used
random number tables (Adam 1998; Bollag 1984). The remaining
trials stated that allocation was random but did not describe the
method (unclear risk of bias).
Only King 2012 described the method of allocation concealment.
An opaque envelope that had been pre-packaged was used to con-
ceal allocation (low risk of bias). The other included trials did not
describe the method of allocation concealment (unclear risk of
bias).
Blinding
Each included trial was only partially blinded (patients, clinicians
or outcome assessors; sometimes two, but not all three), suggesting
some risk of biased results.
In particular, the design of Slapak 2008 made patient blinding
largely impossible as each participant either used the saline spray
or did not. The outcome assessors were blinded only to the type
of saline spray delivery used and not blinded as to whether or not
participants were using the saline treatment (unclear risk of bias).
In King 2012, patient blinding was not achievable as the control
group did not use a nose spray as placebo. The outcome measures
were reported and extracted from a symptom diary so removing
the role of any potential for detection bias (unclear risk of bias).
Wang 2009 did not blind participants to the nasal spray. For the
unreported outcomes of sinusX-ray andnasal smear cytology, both
of the outcome assessors were blinded to treatment allocation.
Blinding was not described for other outcome measures (high risk
of bias).
Participants and clinicians were blinded in Adam 1998, but blind-
ing of outcome assessors was not discussed (low risk of bias). Con-
versely, the outcome assessors in Bollag 1984 were blinded to pa-
tient treatment group but blinding of participants (and parents)
was not discussed (unclear risk of bias).
Incomplete outcome data
Adam 1998 reported 24 of 143 participants lost to follow-up, al-
though a further 35 of the completers failed to submit a complete
symptom checklist. Intention-to-treat analysis was performed (un-
clear risk of bias).
Bollag 1984 reports that 28 of 74 participants were lost to follow-
up, though evenly distributed between trial groups (high risk of
bias).
King 2012 adequately discussed patients lost to follow-up, how-
ever there was a significant difference in numbers lost to follow-
up between the treatment and control groups (high risk of bias).
In Wang 2009 there was no loss to follow-up. However, there are
missing data for two participants for the symptoms scores used in
this review. There is one other participant with missing data for
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an outcome not included in this review (low risk of bias).
Slapak 2008 adequately discussed drop-outs and losses to follow-
up, which numbered only 11 out of the initial 401 participants
enrolled in the trial (low risk of bias).
Selective reporting
Wang 2009 reported statistically significant nasal peak expiratory
flow rates but presented no data for this outcome. The authors
were unable to provide this. Wang 2009 also reported significantly
improved quality of life scores in the nasal saline groupbut againno
data were presented or available to the review authors for inclusion
in this review (high risk of bias).
Other potential sources of bias
The Wang 2009 paper also had methodological weaknesses. Pa-
tients recorded daily symptoms in a symptom diary, but the base-
line score for individual and total symptom score (TSS) was cal-
culated as a mean of daily scores during the baseline period of
seven days, rather than on the day of entry to the trial. We also
noted that there was a statistically significant difference between
the two treatment groups at baseline (which included week one of
treatment) as well as at two and three weeks after treatment. This
could mean that there was a problem with randomisation or that
nasal saline caused the difference within the first week, as these
baseline data are averaged over the first seven days. We also noted
incorrect data in the tables presented in theWang 2009 paper.We
contacted the trial authors who confirmed this error but stated
that the results presented in the text and Table 2 of the paper were
correct (high risk of bias). Other potential sources of bias were not
identified in the other included studies (low risk of bias).
Bollag 1984 provided incomplete data that were not suitable for
pooling, instead reporting onlymean scores for each group at base-
line and follow-up two days later, with baseline scores varying con-
siderably. We could calculate the difference in mean improvement
across the groups from the data given but standard deviations were
not available and we were not able to access original raw data.
Effects of interventions
See: Summary of findings for the main comparison Normal
saline plus standard treatment compared to standard treatment
alone for acute upper respiratory tract infections
The clinical measures used in the included studies were so het-
erogenous as to only allow minimal pooling of data. Other than
time to symptom resolution (assessed both by King 2012 and
Adam 1998) and antibiotic usage (King 2012; Slapak 2008), the
results from each study must be presented individually. Although
nasal symptom score was measured by a few studies, differences
in methods of data collection make pooling of data impossible or
misleading. For example, Adam 1998 reported a nasal symptoms
score that was a composite of both nasal and non-nasal symptoms
(cough, headache), which precluded pooling of data. Wang 2009
also measured nasal symptoms scores. However, the data were av-
eraged over a week-long cycle, without reporting the baseline score
at trial entry, and could not be combined.
Primary outcomes
1. Change in severity of acute upper respiratory tract
infection (URTI)-related symptoms over periods up to 28
days
Nasal symptom score
Three studies reported nasal symptoms at day three. All showed
no difference between the saline nasal irrigation group and the
observation only group (Adam 1998; Bollag 1984; King 2012).
King 2012 rated symptoms on a four-point symptom scale, from
zero (no symptoms) to three (severe symptoms). Bollag 1984 used
a similar scale but reversed, with one representing severe symptoms
and four indicating no symptoms. Both of these studies failed to
adjust for baseline difference, while Adam 1998 used multivariate
linear regression to adjust for baseline severity. Adam 1998 claimed
to use a four-point symptom scale similar to King 2012, but their
results were presented as mean scores up to a maximum of five.
Two studies also reported nasal symptom scores at day seven,
again neither reporting statistical differences between the treat-
ment groups (Adam 1998; King 2012).Wang 2009 compared the
baseline mean score from the first week to the second and third
week score for four nasal and four non-nasal symptoms, and re-
ported no statistical difference in symptoms scores, with the ex-
ception of daytime rhinorrhoea and nocturnal nasal congestion (P
value < 0.05).
Slapak 2008 reported a significant reduction nasal secretion score
at visit two (up to three weeks after enrolment) for all nasal saline
groups compared to control as a mean difference (MD) of -0.31
(95% confidence interval (CI) -0.48 to -0.14) on a four-point
scale.
Nasal secretion type
Participants studied by Slapak 2008 were assessed at the first and
second visits (up to three weeks from study entry) for type of nasal
secretions and the qualitative assessment (absent, serous, seropu-
rulent or purulent) was translated to a numerical score for group-
ing of results. For this comparison of the saline wash and control
groups at the second visit on a four-point scale the MD was -0.34
(95% CI -0.50 to -0.18), indicating a small improvement with
nasal saline irrigation.
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Nasal patency
Slapak 2008 evaluated the degree of difficulty of nasal breathing
as a four-point “breathing score” for each patient at the first and
second visits. The difference for the saline wash group compared
with the control group at the second visit was MD -0.33 (95% CI
-0.47 to -0.19).
Wang 2009 recorded nasal peak expiratory flow rate at three inter-
vals during their study period. The authors reported a statistically
significant mean improvement in nasal peak expiratory flow rate
for the normal saline group at an undisclosed medium time point
and end of study time point. However, no raw data were available
and therefore we cannot report the size of this difference nor com-
ment on the clinical significance. Baseline differences were also
not reported.
Respiratory symptom score
Only one included study, examining infants and children up to 24
months of age, provided respiratory symptom scores for each group
of patients (Bollag 1984). This score included cough and difficulty
in breathing. At day three, there was no significant difference in
respiratory symptom score between any of the compared treatment
or control groups based on a direct comparison to group scores
on day three. However, the saline group improved by 0.91 from
baseline compared to 0.26 for the phenylephrine group and 0.80
for the control group on a four-point scale.
Activity symptom score
This is a score reflecting the child’s degree of wellness in terms of
behaviours such as feeding, playing and sleeping. Analysis of the
data for activity symptom score at day three showed no difference,
statistical or otherwise, between any of the compared treatment or
control groups (Bollag 1984).
Overall health status
Slapak 2008 included health status scores, indicating the degree
of symptomatic improvement based on patient reports (Table 1).
Scores were given on a scale of one to four, with a health status score
of one indicating cure and a score of four representing no change.
The mean health status score at the follow-up examination for the
subgroups ’entry during cold’ and ’entry during flu’ respectively
was 2.6 (standard deviation (SD) 1.02) and 2.00 (SD 0.91) for
the control group, compared with 1.87 (SD 0.84) and 1.59 (SD
0.74) for the saline wash group, with a P value of < 0.05 reported
for both groups.
2. Time to resolution of symptomatic illness
Two studies included data on the ’day of well-being’ for patients
in each group, indicating on which day participants felt ’back
to normal’ (Adam 1998; King 2012). Adam 1998 reported the
mean day of well-being for the three study groups and found
no statistically significant difference in mean day of well-being
between any of the groups (Table 2).
King 2012 measured ’day to wellness’ of participants who were
asked to fill out a symptom diary. The mean day of well-being for
the group treated with isotonic nasal saline was 7.67 days (95%CI
5.33 to 10.00) compared to 10.48 days (95% CI 8.03 to 12.93)
for the control group. This was not a statistically significant dif-
ference. The pooled data for King 2012 and Adam 1998 showed
no significant difference between normal saline and the control
group (Analysis 1.1)
Secondary outcomes
1. Adverse events associated with treatment
Three studies reported adverse effects from treatment with nasal
saline, or difficulty with patient toleration of treatment. The study
using infant patients reported that six out of 15 participants
(40.0%) did not tolerate treatment with saline nasal drops, while
seven out of 16 (43.7%) did not tolerate treatment with phenyle-
phrine drops (Bollag 1984). While the group numbers are small,
the similar proportions suggest that the infants may not have tol-
erated the delivery of nasal drops, rather than the saline itself.
In the study using adult patients with the common cold or rhinos-
inusitis, in the group using hypertonic saline irrigation seven out
of 33 participants (21.2%) complained of dry nose and 11 out of
33 (33.3%) reported pain or irritation (Adam 1998). Among the
group treated with normal saline irrigation, 11 out of 36 (30.5%)
complained of dry nose and four out of 31 (12.9%) reported pain
or irritation from the treatment (P value = 0.05 for nasal irrita-
tion).
The third study, using children, found an overall rate of adverse
events of 8.7%, most of which were reported by participants in
the medium jet group and associated with the higher flow rate
(Slapak 2008). The rates of adverse effects were not reported for
the control group, only the reporting of rates for all the saline
intervention groups. The trial authors did not specify further the
type of complaints butmention that three participants experienced
nosebleeds.
As none of the trials discussed patient withdrawal in detail, it is
possible that some may have left the studies for reasons related to
adverse effects or discomfort from treatment.
2. Days off work or school
Only King 2012 reported days off work with no significant dif-
ference between groups (1.3 days for the control group versus 1.9
for the saline group).
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3. Antibiotic and URTI medication use
King 2012 and Slapak 2008 compared the use of antibiotics in
saline groups versus controls and found a trend to reduced an-
tibiotic use in the nasal saline group, though this did not reach
statistical significance (Analysis 2.1).
Slapak 2008 did report statistically significant reductions in nasal
decongestant and mucolytic medication used for symptomatic re-
lief in the saline groups (P value < 0.5) (Table 3).
D I S C U S S I O N
Summary of main results
The five included randomised controlled trials (RCTs) of saline
nasal irrigation provide limited evidence that treatment is effec-
tive for symptoms of acute upper respiratory tract infections (UR-
TIs). Nasal symptom scores, combined from a complex of differ-
ent symptoms in different trials, were statistically similar between
treatment and control groups. There was a reduction in the out-
come of time to resolution of symptoms, which was reported in
two trials, but the difference was not clinically significant. The
largest trial, which also had a high risk of bias, reported a number
of statistically significant outcomes for the nasal saline group at
follow-up, including reduction of sore throat, nasal secretion and
secretion type and nasal breathing score (Slapak 2008). It also re-
ported a significant improvement in the health status score.
There was a trend towards reduced antibiotic use in one study with
saline nasal irrigation and this study also demonstrated a statisti-
cally significant reduction in the use of adjunct nasal decongestant
treatment with nasal saline irrigation compared to control (Slapak
2008). One study, reported a significant difference in quality of
life and peak nasal expiratory flow (Wang 2009). However, there
were significant methodological and reporting flaws that limit the
interpretation of these data.
No serious adverse effects occurred in the included trials, although
three children in one study experienced nosebleeds (Slapak 2008).
Minor adverse events were not uncommon and 40% to 44% of
babies were shown to have difficulty with nasal drops. Discomfort
in one studywas associatedwith higher applicationpressures rather
than the nasal saline solution itself (Slapak 2008).
Overall completeness and applicability of
evidence
This review focused on RCTs of saline nasal irrigation for the
symptomatic treatment of acute URTIs. The nature of saline
nasal irrigation makes double-blinding difficult and an appropri-
ate placebo difficult to find. There were a limited number of RCTs
available and all of these studies were small in size. Of the five
included trials, only two main outcomes could be combined for
pooled analysis due to the differences in the clinical measures used.
The two additional studies included since the original systematic
review have not contributed data of sufficient size or quality to
materially change the original findings (King 2012; Wang 2009).
Each trial revieweduseddifferent strengths of saline solution, again
limiting the possibilities for data comparison. In particular, Slapak
2008 used a commercial isotonic seawater product containing zinc
and other elements that may be a factor in the effects of the prod-
uct.
Only one of the included papers examined the effect of saline
irrigation on other symptoms, such as anosmia (loss of the sense
of smell) and cough associated with acute URTIs (Slapak 2008).
This is a potential clinical application of the treatment but we
located no other papers addressing the topic.
The clinical outcomes measured by each study were largely subjec-
tive, focusing on patient-reported symptoms, which increases risk
of bias in the results. Furthermore, Bollag 1984 and Wang 2009
relied on interpretation and reporting of infant patients’ symptoms
by parents, contributing to potential bias and this is a limitation
in the interpretation of the results of these studies.
Two excluded studies, although excluded for not meeting the in-
clusion criteria, provided some corroborating evidence to support
the need for future research that is better structured and controlled
to investigate nasal saline irrigation as a treatment for acute URTIs
(Inanli 2002; Passali 2005). The measure of mucociliary clearance
(measured by Inanli 2002) is not clinically relevant and data re-
lating to symptom relief and duration of illness would be more
useful.
Quality of the evidence
The summary of the evidence is presented in the Summary of
findings for the main comparison. For nasal saline versus a stan-
dard therapy or observation, we judged the evidence for a reduc-
tion in nasal symptoms or time to wellness to be of very low or low
quality, meaning that we cannot have a high degree of confidence
in this result. The studies are generally at unclear risk of bias and
the sample sizes are small (most with fewer than 100 participants
overall) and the possibility of chance findings and publication bias
is high. Most of the data come from one or two trials. Further
research is very likely to have an important impact on our confi-
dence in the estimate of effect.
Potential biases in the review process
We included one unpublished study in this updated review (King
2012). This unpublished trial was supervised by one of the authors
(DK), whose role in the trial was as a supervisor and clinician. The
’Risk of bias’ assessment and data extraction were undertaken by
independent authors (BM, CW), who had no role in this trial.
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A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Limited data from five randomised controlled trials (RCTs) sug-
gest that saline nasal irrigation may have some benefit in patients
with acute upper respiratory tract infections (URTIs). While some
participants experienced minor discomfort, no serious side effects
were identified. Nasal irrigation with saline is a safe treatment that
may be mildly beneficial to some patients, though the existing ev-
idence is too limited to support recommendations for or against
its role as a standard intervention.
Implications for research
The two new studies added to this review have not changed the
findings from the last published review. However, further well-de-
signed, sufficiently large and well-conducted RCTs are warranted
to establish the place of nasal saline irrigation in acute URTIs. Fur-
ther research should include clinically relevant respiratory symp-
toms as outcome measures, including cough. Given the range of
different available topical saline treatments, future studies could
include comparisons of liquid washes to sprays in the treatment
of URTIs.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Adam 1998
Methods Randomised controlled trial. 1 year duration
Participants 143 adults with common cold or acute rhinosinusitis, with symptoms for less than 3
weeks duration, were randomised. Conducted in Minnesota, USA. 119 participants
contributed data for analysis
Interventions Hypertonic saline spray, 2 squirts in each nostril 3 times a day
Normal saline spray, 2 squirts in each nostril 3 times a day
No treatment, observation only
Treatment continued until resolution of symptoms
Outcomes Nasal symptom score on day 3
Time to symptom resolution (day of well-being)
Additional OTC treatment required
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random numbers table used
Allocation concealment (selection bias) Unclear risk Not mentioned in paper
Blinding (performance bias and detection
bias)
All outcomes
Low risk Patients and clinicians blinded; outcome
assessors not discussed
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Drop-out and losses to follow-up not dis-
cussed. 24 participants (16%) were lost to
follow-up
Selective reporting (reporting bias) Unclear risk Intention-to-treat analysis performed; orig-
inal study protocol not available
Other bias Low risk Noother potential sources of bias identified
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Bollag 1984
Methods Randomised controlled trial. November and December 1980
Participants 74 children were randomised, from 3 weeks to 2 years of age, with unspecified acute
upper respiratory infections. Los Angeles, California, USA. 46 children contributed data
for analysis
Interventions Saline nose drops, 0.9%, 4 drops in each nostril every 2 hours as needed
Phenylephrine nose drops, 0.25% solution, 4 drops 4 times a day for no more than 3
days
No treatment
Outcomes Measured at 2 days after first visit
Nasal symptom score
Respiratory symptom severity
Activity signs
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random numbers table used
Allocation concealment (selection bias) Unclear risk Not mentioned in paper
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Outcome assessors blinded; others (includ-
ing patients/parents) not blinded, control
group had no comparable intervention to
the intervention groups
Incomplete outcome data (attrition bias)
All outcomes
High risk Drop-outs and losses to follow-up ade-
quately discussed; 28 out of 74 participants
dropped out, equal in all 3 groups
Selective reporting (reporting bias) Unclear risk Intention-to-treat analysis not performed;
original study protocol not available
Other bias Low risk Noother potential sources of bias identified
King 2012
Methods Randomised controlled trial. 2010 to 2012
Participants 62 adults with common cold or URTI diagnosed clinically, Brisbane, Australia. 33
participants contributed data for analysis
20Saline nasal irrigation for acute upper respiratory tract infections (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
King 2012 (Continued)
Interventions Saline nasal spray, plus usual treatment. Normal saline, instructed to use 2 to 3 sprays in
each nostril at least 4 times daily
Control group - usual treatment apart from any other medication delivered by nose spray
Outcomes Day to wellness
Symptom score
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated blocks of 10 for ran-
domisation
Allocation concealment (selection bias) Low risk Allocation done using opaque envelopes
that were pre-packaged
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Participants know which allocation they
have received by the nature of their treat-
ment
Outcome assessed by patient reporting via
symptom diary only
Incomplete outcome data (attrition bias)
All outcomes
High risk Adequately described but many more par-
ticipants lost to follow-up in the treatment
group compared with placebo. Only 33 of
62 enrolled completed follow-up
Selective reporting (reporting bias) Low risk All reported on adequately as pre-de-
scribed; original study protocol was avail-
able
Other bias Low risk Recruited from attending GPs who may
have biased more serious infections - un-
likely to have affected outcome
Slapak 2008
Methods Randomised controlled trial. Multicentre, open-label. January to April 2006
Participants 401 children aged 6 to 10 years, with common cold or influenza. Czech Republic. 390
contributed study data
Interventions 3 groups randomised to receive different delivery methods of isotonic saline (sea water)
, delivered 6 times per day, plus standard treatments
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Slapak 2008 (Continued)
Group 1 - medium jet flow
Group 2 - fine spray
Group 3 - eye and nose wash with a fine spray
The 4th group received standard treatments only (control group)
Outcomes Nasal symptom and breathing scores
Health status score
Additional treatment required
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Sequence of clinic arrival used for alloca-
tion
Allocation concealment (selection bias) Unclear risk Not mentioned in paper
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk No patient blinding possible due to study
design; outcome assessors blinded to saline
delivery method but not to intervention
versus control
Incomplete outcome data (attrition bias)
All outcomes
Low risk Drop-out and losses to follow-up small
and adequately discussed. 390 of 401 com-
pleted the study (11 lost to follow-up)
Selective reporting (reporting bias) Unclear risk Intention-to-treat analysis not performed;
original study protocol not available
Other bias Low risk Noother potential sources of bias identified
Wang 2009
Methods Randomised controlled trial. December 2006 to June 2008
Participants 69 children, aged 3 to 12 years, with acute sinusitis. Taiwan. 2 evidently lost to follow-
up
Interventions Normal saline nasal irrigation, with 15 to 20 ml each nostril, 1 to 3 times a day and
standard treatments
Standard treatments only
Outcomes Nasal symptom score
Paediatric Rhinoconjunctivitis Quality of Life Score
Nasal peak expiratory flow rate
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Wang 2009 (Continued)
Nasal smear
Sinus X-ray
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Correspondence from authors confirmed
randomisation but no detail on method
Allocation concealment (selection bias) Unclear risk Not described in paper, nor obtained from
authors. 30 participants assigned to inter-
vention and 39 to placebo group. Signifi-
cant differences between groups at baseline,
particularly in rhinorrhoea score
Blinding (performance bias and detection
bias)
All outcomes
High risk Poorly described. Most outcome measures
were not blinded to participants or re-
searchers. Some outcomes were objective
measures, less vulnerable to bias
Incomplete outcome data (attrition bias)
All outcomes
Low risk There is a comparatively small loss of par-
ticipant data (2 out of 69 not included) but
no explanation in the paper
Selective reporting (reporting bias) High risk Not all of the study’s pre-specified primary
outcomes have been reported; some out-
comes of interest in the review are reported
incompletely
In addition, there are errors in the reported
tabulated data. We clarified with the au-
thors which data are correct before includ-
ing data in our review
Other bias High risk In addition to the above, there are some
methodological flaws,mainly the averaging
of symptoms over a week, especially over
the first week that included a baseline mea-
surement. We noted that from the data we
cannot conclude that the groups were equal
at baseline, nor that the improvement was
due to an early treatment effect. We asked
the authors to address this issue, with no
reply
OTC = over the counter
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URTI = upper respiratory tract infection
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Inanli 2002 Failed to meet the inclusion criteria, as no clinically relevant outcomes measured
Method of allocation concealment not described
No blinding
Selection bias not controlled
Passali 2005 Failed to meet the inclusion criteria, as no comparison group as a control; both groups in the trial received nasal saline
via different delivery methods
Methods of randomisation and allocation concealment not described
Doubt as to randomisation used
No blinding
Intention-to-treat analysis not performed
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D A T A A N D A N A L Y S E S
Comparison 1. Time to symptom resolution
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mean days to wellness (normal
saline plus standard therapy
versus standard therapy)
2 111 Mean Difference (IV, Random, 95% CI) -0.79 [-4.72, 3.14]
Comparison 2. Antibiotic use
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Antibiotic usage (normal saline
plus standard therapy versus
standard therapy)
2 422 Odds Ratio (M-H, Random, 95% CI) 0.64 [0.29, 1.44]
Analysis 1.1. Comparison 1 Time to symptom resolution, Outcome 1 Mean days to wellness (normal saline
plus standard therapy versus standard therapy).
Review: Saline nasal irrigation for acute upper respiratory tract infections
Comparison: 1 Time to symptom resolution
Outcome: 1 Mean days to wellness (normal saline plus standard therapy versus standard therapy)
Study or subgroup Normal saline Standard therapy
Mean
Difference Weight
Mean
Difference
N Mean(SD)[Days] N Mean(SD)[Days] IV,Random,95% CI IV,Random,95% CI
Adam 1998 43 9.2 (7.4735) 35 8 (3.7844) 50.4 % 1.20 [ -1.36, 3.76 ]
King 2012 10 7.67 (3.57) 23 10.48 (3.57) 49.6 % -2.81 [ -5.46, -0.16 ]
Total (95% CI) 53 58 100.0 % -0.79 [ -4.72, 3.14 ]
Heterogeneity: Tau2 = 6.27; Chi2 = 4.55, df = 1 (P = 0.03); I2 =78%
Test for overall effect: Z = 0.39 (P = 0.69)
Test for subgroup differences: Not applicable
-50 -25 0 25 50
Favours normal saline Favours standard treatment
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Analysis 2.1. Comparison 2 Antibiotic use, Outcome 1 Antibiotic usage (normal saline plus standard
therapy versus standard therapy).
Review: Saline nasal irrigation for acute upper respiratory tract infections
Comparison: 2 Antibiotic use
Outcome: 1 Antibiotic usage (normal saline plus standard therapy versus standard therapy)
Study or subgroup Normal saline Standard therapy Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
King 2012 1/10 2/23 10.2 % 1.17 [ 0.09, 14.56 ]
Slapak 2008 16/288 9/101 89.8 % 0.60 [ 0.26, 1.41 ]
Total (95% CI) 298 124 100.0 % 0.64 [ 0.29, 1.44 ]
Total events: 17 (Normal saline), 11 (Standard therapy)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.24, df = 1 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 1.07 (P = 0.28)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours normal saline Favours standard treatment
A D D I T I O N A L T A B L E S
Table 1. Patient-reported health status score following acute phase (Slapak 2008)
Treatment group Health status score
Symptomatic improvement compared to
beginning of illness
- Normal treatment only
2.60 (SD 1.02) - cold
2.00 (SD 0.91) - flu
Symptomatic improvement compared to
beginning of illness
- Normal treatment plus isotonic saline
1.87 (SD 0.84) - cold
1.59 (SD 0.74) - flu
Reported as significant findings (see Results section). Insufficient data to calculate confidence intervals.
SD: standard deviation
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Table 2. Day of well-being (Adam 1998)
Treatment group Day of well-being
Hypertonic saline irrigation 8.3 days (95% CI 6.9 to 9.7)
Normal saline irrigation 8.3 days (95% CI 6.82 to 9.78)
Observation only 8.0 days (95% CI 6.7 to 9.3)
CI: confidence interval
Table 3. Use of additional medications (Slapak 2008)
Medication type Use before study (%) Use at follow-up (%)
Antipyretics 23.8 (control)
23.5 (saline wash)
12.9 (control)
7.6 (saline wash)
Decongestants 40.0 (control)
29.4 (saline wash)
35.6 (control)
15.9 (saline wash)
Mucolytics 20.0 (control)
15.6 (saline wash)
31.7 (control)
17.3 (saline wash)
Systemic antibiotics 5.0 (control)
3.1 (saline wash)
8.9 (control)
5.5 (saline wash)
A P P E N D I C E S
Appendix 1. Previous search strategy
We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2009, issue 2), which contains
the Acute Respiratory Infections (ARI) Group’s Specialised Register, MEDLINE (1966 to May 2009), EMBASE (1974 to May 2009),
CINAHL (1982 to May 2009), AMED (1985 to 2009) and LILACS (May 2009).
The following search terms were used to search MEDLINE and CENTRAL. The MEDLINE search was combined with the Cochrane
Highly Sensitive Search Strategy for identifying randomised trials in MEDLINE; sensitivity-maximising version (2008 revision); Ovid
format (Lefebvre 2011). The search terms were modified to search other databases. See Appendix 2 for the EMBASE search strategy.
MEDLINE (Ovid)
1 exp Respiratory Tract Infections/
2 (respiratory tract infection* or upper respiratory infection*).tw.
3 urti.tw.
4 Rhinitis/
27Saline nasal irrigation for acute upper respiratory tract infections (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
5 rhinit*.tw.
6 Common Cold/
7 common cold*.tw.
8 exp Pharyngitis/
9 pharyngit*.tw.
10 sore throat*.tw.
11 Tonsillitis/
12 tonsillit*.tw.
13 exp Sinusitis/
14 sinusit*.tw.
15 exp Laryngitis/
16 laryngit*.tw.
17 rhinosinusit*.tw.
18 rhinorrhea*.tw.
19 Influenza, Human/
20 flu*.tw.
21 runny nose*.tw.
22 rhinorrhoea*.tw.
23 ((nasal* or nose*) adj2 congest*).tw.
24 or/1-22
25 Sodium Chloride/
26 (saline or salt* or sodium chloride*).tw,nm.
27 or/25-26
28 Irrigation/
29 (irrigat* or lavage* or wash* or rins* or douch* or atomis* or atomiz*).tw.
30 or/28-29
31 (nasal* or nose*).tw.
32 Nose/
33 32 or 31
34 30 and 33
35 exp Nasal Lavage/
36 or/34-35
37 24 and 27 and 36
Embase.com
1. ’respiratory tract infection’/de OR ’upper respiratory tract infection’/de OR ’rhinitis’/de OR ’common cold’/de OR ’pharyngitis’/de
OR ’tonsillitis’/de OR ’sore throat’/de OR ’sinusitis’/de OR ’laryngitis’/de OR ’rhinosinusitis’/de OR ’influenza’/de
2. ’respiratory tract infection’:ti,ab OR ’respiratory tract infections’:ti,ab OR ’upper respiratory infection’:ti,ab OR ’upper respiratory
tract infections’:ti,ab OR urti:ti,ab OR rhinit*:ti,ab OR ’common cold’:ti,ab OR ’common colds’:ti,ab OR pharyngit*:ti,ab OR ’sore
throat’:ti,ab OR ’sore throats’:ti,ab OR tonsillit*:ti,ab OR sinusit*:ti,ab OR laryngit*:ti,ab OR rhinosinusit*:ti,ab OR rhinorrhea:ti,ab
OR rhinorrhoea:ti,ab OR ’runny nose’:ti,ab OR ’runny noses’:ti,ab OR flu:ti,ab OR influenza*:ti,ab
3. #1 OR #2
4. ’nose’/de
5. nasal*:ti,ab OR nose*:ti,ab
6. #4 OR #5
7. lavage*:ti,ab OR wash*:ti,ab OR irrigat*:ti,ab OR rins*:ti,ab OR douch*:ti,ab OR atomis*:ti,ab OR atomiz*:ti,ab
8. #6 AND #7
9. ’sodium chloride’/de
10. salt*:ti,ab OR ’sodium chloride’:ti,ab OR saline*:ti,ab
11. #9 OR #10
12. #8 AND #11
13. #3 AND #12
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14. random*:ti,ab OR placebo*:ti,ab,de OR ’double blind’:ti,ab
15. #13 AND #14
Appendix 2. MEDLINE (Ovid) search strategy
1 exp Respiratory Tract Infections/
2 (infect* adj3 upper respiratory).tw.
3 urti.tw.
4 Rhinitis/
5 rhinit*.tw.
6 Common Cold/
7 common cold*.tw.
8 exp Pharyngitis/
9 pharyngit*.tw.
10 sore throat*.tw.
11 Tonsillitis/
12 tonsillit*.tw.
13 exp Sinusitis/
14 sinusit*.tw.
15 exp Laryngitis/
16 laryngit*.tw.
17 (rhinosinusit* or nasosinusit*).tw.
18 Influenza, Human/
19 flu*.tw.
20 (rhinorrhoea* or rhinorrhea*).tw.
21 ((nasal or nose*) adj2 (congest* or discharg* or blocked or runny or running or stuffy or stuffed)).tw.
22 (infect* adj3 (nose* or throat* or sinus* or sinonasal or sino-nasal or pharyn* or laryn*)).tw.
23 or/1-22
24 Therapeutic Irrigation/
25 Nose/
26 (nasal or nose*).tw.
27 25 or 26
28 24 and 27
29 ((nasal or nose*) adj5 (irrigat* or lavage* or wash* or rins* or douch* or atomis* or atomiz*)).tw.
30 Nasal Lavage/
31 or/28-30
32 Sodium Chloride/
33 (saline or salt* or sodium chloride*).tw,nm.
34 or/32-33
35 31 and 34
36 23 and 35
29Saline nasal irrigation for acute upper respiratory tract infections (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Appendix 3. Embase.com search strategy
#38. #34 AND #37
#37. #35 OR #36
#36. random*:ab,ti OR placebo*:ab,ti OR crossover*:ab,ti OR ’cross over’:ab,ti OR ’cross-over’:ab,ti OR factorial*:ab,ti OR volunteer*:
ab,ti OR assign*:ab,ti OR allocat*:ab,ti OR ((singl* OR doubl*) NEAR/1
(blind* OR mask*)):ab,ti
#35. ’randomized controlled trial’/expOR ’single blind procedure’/exp OR ’double blind procedure’/expOR ’crossover procedure’/exp
#34. #31 AND #33
#33. #19 OR #32
#32. ’nose congestion’/de
#31. #22 AND #30
#30. #27 OR #28 OR #29
#29. ((nasal OR nose*) NEAR/5 (irrigat* OR lavage* OR wash* OR rins* OR douch* OR atomis* OR atomiz*)):ab,ti
#28. ’nasal lavage’/de
#27. #23 AND #26
#26. #24 OR #25 79,351
#25. nose*:ab,ti OR nasal:ab,ti
#24. ’nose’/de
#23. ’lavage’/de
#22. #20 OR #21 249,100
#21. saline:ab,ti OR salt*:ab,ti OR ’sodium chloride’:ab,ti
#20. ’sodium chloride’/de
#19. #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16
OR #17 OR #18
#18. influenz*:ab,ti OR flu:ab,ti
#17. ’influenza’/exp
#16. (infect* NEAR/3 (nose* OR throat* OR sinus* OR sinonasal OR ’sino-nasal’ OR pharyn* OR laryng*)):ab,ti
#15. ((nasal OR nose*) NEAR/2 (congest* OR discharg* OR blocked* OR runny OR running OR stuffy OR stuffed)):ab,ti
#14. rhinorrhoea:ab,ti OR rhinorrhea:ab,ti
#13. ’rhinorrhea’/de
#12. laryngit*:ab,ti
#11. ’laryngitis’/de OR ’laryngotracheobronchitis’/de
#10. tonsillit*:ab,ti
#9. ’tonsillitis’/de
#8. ’sore throat’:ab,ti OR ’sore throats’:ab,ti
#7. pharyngit*:ab,ti
#6. ’pharyngitis’/de OR ’viral pharyngitis’/de
#5. rhinit*:ab,ti OR ’common cold’:ab,ti OR ’common colds’:ab,ti OR rhinosinusit*:ab,ti OR nasosinusit*:ab,ti OR rhinopharyngit*:
ab,ti OR nasopharyngit*:ab,ti
#4. ’rhinitis’/de OR ’common cold’/de OR ’rhinopharyngitis’/de OR ’rhinosinusitis’/de
#3. urti:ab,ti
#2. (infect* NEAR/3 ’upper respiratory’):ab,ti
#1. ’upper respiratory tract infection’/exp
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Appendix 4. CINAHL (Ebsco) search strategy
S42 S32 and S41
S41 S33 or S34 or S35 or S36 or S37 or S38 or S39 or S40
S40 (MH “Quantitative Studies”)
S39 TI placebo* or AB placebo*
S38 (MH “Placebos”)
S37 TI random* or AB random*
S36 TI (singl* blind* or doubl* blind* or tripl* blind* or trebl* blind* or singl* mask* or doubl* mask* or trebl* mask* or tripl* mask*)
or AB (singl* blind* or doubl* blind* or tripl* blind* or trebl* blind* or singl* mask* or doubl* mask* or trebl* mask* or tripl* mask*)
S35 TI clinic* trial* or AB clinic* trial*
S34 PT
S33 (MH “Clinical Trials+”)
S32 S21 and S31
S31 S24 and S27 and S30
S30 S28 or S29
S29 TI (nose* or nasal) or AB (nose* or nasal)
S28 (MH “Nose”)
S27 S25 or S26
S26 TI ( irrigat* or lavage* or wash* or rins* or douch* or atomis* or atomiz* ) or AB ( irrigat* or lavage* or wash* or rins* or douch*
or atomis* or atomiz* )
S25 (MH “Irrigation”)
S24 S22 or S23
S23 TI (saline or salt* or sodium chloride) or AB (saline or salt* or sodium chloride)
S22 (MH “Sodium Chloride”)
S21 S1 or S2 or S3 or S4 or S5 or S6 or S7 or S8 or S9 or S10 or S11 or S12 or S13 or S14 or S15 or S16 or S17 or S18 or S19 or S20
S20 TI (influenza* or flu) or AB (influenza* or flu)
S19 (MH “Influenza, Human+”)
S18 TI (infect* N3 nose* or infect* N3 throat* or infect* N3 sinus* or infect* N3 sinonasal* or infect* N3 sino-nasal* or infect* N3
pharyn* or infect* N3 laryn*) or AB (infect* N3 nose* or infect* N3 throat* or infect* N3 sinus* or infect* N3 sinonasal* or infect*
N3 sino-nasal* or infect* N3 pharyn* or infect* N3 laryn*)
S17 TI (nose* N2 congest* or nose* N2 discharg* or nose* N2 blocked or nose* N2 runny or nose* N2 running or nose* N2 stuffy
or nose* N2 stuffed) or AB (nose* N2 congest* or nose* N2 discharg* or nose* N2 blocked or nose* N2 runny or nose* N2 running
or nose* N2 stuffy or nose* N2 stuffed)
S16 TI (nasal N2 congest* or nasal N2 discharg* or nasal N2 blocked or nasal N2 runny or nasal N2 running or nasal N2 stuffy or
nasal N2 stuffed) or AB (nasal N2 congest* or nasal N2 discharg* or nasal N2 blocked or nasal N2 runny or nasal N2 running or nasal
N2 stuffy or nasal N2 stuffed)
S15 TI (rhinorrhoea or rhinorrhea) or AB (rhinorrhoea or rhinorrhea)
S14 TI laryngit* or AB laryngit*
S13 TI sinusit* or AB sinusit*
S12 (MH “Sinusitis”)
S11 TI tonsillit* or AB tonsillit*
S10 (MH “Tonsillitis”)
S9 TI sore throat* or AB sore throat*
S8 TI pharyngit* or AB pharyngit*
S7 (MH “Pharyngitis”)
S6 TI common cold* or AB common cold*
S5 (MH “Common Cold”)
S4 TI (rhinit* or rhinosinusit* or nasosinusit*) or AB (rhinit* or rhinosinusit* or nasosinusit*)
S3 (MH “Rhinitis”) OR (MH “Rhinosinusitis”)
S2 TI ( upper respiratory infect* or upper respiratory tract infect* or urti ) or AB ( upper respiratory infect* or upper respiratory tract
infect* or urti )
S1 (MH “Respiratory Tract Diseases+”)
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Appendix 5. AMED (Ovid) search strategy
1 exp respiratory tract infections/
2 (infect* adj3 upper respiratory).tw.
3 urti.tw.
4 rhinitis/
5 rhinit*.tw.
6 common cold*.tw.
7 common cold/
8 pharyngitis/
9 pharyngit*.tw.
10 sore throat*.tw.
11 tonsillitis/
12 tonsillit*.tw.
13 sinusitis/
14 sinusit*.tw.
15 laryngit*.tw.
16 (rhinosinusit* or nasosinusit*).tw.
17 (rhinorrhea or rhinorrhoea).tw.
18 influenza/
19 (influenza* or flu).tw.
20 ((nasal or nose*) adj2 (congest* or discharg* or blocked or runny or running or stuffy or stuffed)).tw.
21 (infect* adj3 (nose* or throat* or sinus* or sinonasal* or sino-nasal* or pharyn* or laryn*)).tw.
22 or/1-21
23 salts/
24 (salt* or saline* or sodium chloride*).tw.
25 23 or 24
26 irrigation/
27 (irrigat* or lavage* or wash* or rins* or douch* or atomis* or atomiz*).tw.
28 26 or 27
29 25 and 28
30 22 and 29
Appendix 6. LILACS (BIREME) search strategy
> Search > (MH:“Respiratory Tract Infections” OR “Infecciones del Sistema Respiratorio” OR “Infecções Respiratórias” OR MH:
C01.539.739$ OR MH:C08.730$ OR “upper respiratory infection” OR “upper respiratory tract infections” OR “upper respiratory
infections”OR“upper respiratory tract infection”ORMH:rhinitisORRinitisORRiniteORMH:C08.460.799ORMH:C08.730.674
ORMH:C09.603.799 OR rhinit$ ORMH:“Common Cold” OR “common cold” OR “common colds” OR “Resfriado Común” OR
“Resfriado Comum” OR coryza OR MH:C02.782.687.207 OR MH:C08.730.162 OR MH:pharyngitis OR Faringitis OR Faringite
OR “sore throat”OR “sore throats”ORpharyngit$ORMH:C07.550.781$ORMH:C08.730.561$ORMH:C09.775.649$ORMH:
Tonsillitis OR Tonsilitis OR Tonsilite OR MH:Sinusitis OR sinusit$ OR MH:C08.460.692.752$ OR MH:C08.730.749$ OR MH:
C09.603.692.752$ OR MH:Laryngitis OR Laringitis OR Laringite OR MH:C08.360.535$ OR C08.730.368$ OR C09.400.535$
OR rhinosinusit$ OR nasosinusit$ ORMH:“Influenza, Human” OR “Gripe Humana” OR “Influenza Humana” OR Grippe OR flu*
OR rhinorrhoea OR rhinorrhea) AND (MH:“Therapeutic Irrigation” OR “Irrigación Terapéutica” OR “Irrigação Terapêutica” OR
douch$ OR lavage OR wash$ OR rins$ OR irrigat$ OR atomis$ OR atomiz$ OR MH:E02.533.500 OR E05.927 OR MH:“nasal
lavage” OR “Lavado Nasal” OR “Lavagem Nasal” OR MH:E05.927.573) AND (MH:“sodium
chloride” OR “Cloruro de Sodio” OR “Cloreto de Sódio” OR MH:D01.857.650$ OR MH:D01.210.450.150.875 OR MH:
SP4.011.097.039.729.735 OR salt$ OR salin$ OR “sodium chloride”) > clinical˙trials
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WH A T ’ S N E W
Last assessed as up-to-date: 13 August 2014.
Date Event Description
13 August 2014 New search has been performed Two new studies are included in this update (King 2012;
Wang 2009).
13 August 2014 New citation required but conclusions have not changed Our conclusions remain unchanged. We added a ’Risk
of bias’ assessment table, with some changes in the classi-
fication of the quality of the evidence from the included
trials
H I S T O R Y
Protocol first published: Issue 4, 2007
Review first published: Issue 3, 2010
Date Event Description
16 August 2013 New citation required but conclusions have not changed Review update in progress.
16 August 2008 Amended Converted to new review format.
C O N T R I B U T I O N S O F A U T H O R S
David King (DK), Ben Mitchell (BM) and Chris Williams (CW) reviewed the search results, performed ’Risk of bias’ assessments,
managed data and drafted the final review. Geoffrey Spurling (GS) gave advice on performing the review and assisted with ’Risk of
bias’ assessment.
D E C L A R A T I O N S O F I N T E R E S T
David King: supervisor and enrolling clinician for the unpublished King 2012 study. This study is currently being prepared for
submission for publication.
Ben Mitchell: none known.
Christopher P Williams: none known.
Geoffrey KP Spurling: none known.
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We undertook ’Risk of bias’ assessment of all new and previously included studies following the new Cochrane recommendations.
Some changes in reporting and interpretation of the data from studies included in the original review have occurred. These include
changing the status of two studies from exclusion due to high risk of bias to exclusion due to not meeting the inclusion criteria for
this review (Inanli 2002; Passali 2005). We changed the primary and secondary outcome measures to avoid duplication; for example,
duration of symptoms was a primary outcome in the original review while time to resolution of symptoms was a secondary outcome.
Also, we noted the inclusion of the outcome ’time off work or school’ from Slapak 2008 in the original review to be based on follow-
up periods outside of the specifications for acute URTIs as specified in the protocol, so we omitted this from inclusion in this 2014
update.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Acute Disease; Common Cold [therapy]; Laryngitis [therapy]; Nasal Lavage [adverse effects; ∗methods]; Pharyngitis [therapy]; Ran-
domized Controlled Trials as Topic; Respiratory Tract Infections [∗therapy]; Rhinitis [therapy]; Sinusitis [therapy]; Sodium Chloride
[adverse effects; ∗therapeutic use]
MeSH check words
Adult; Child; Humans
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